Micropapillary pattern is associated with the development of brain metastases and the reduction of survival time in EGFR-mutation lung adenocarcinoma patients with surgery

被引:15
|
作者
Li, Changhui [1 ]
Shen, Yinchen [1 ]
Hu, Fang [1 ]
Chu, Tianqing [1 ]
Yang, Xiaohua [2 ]
Shao, Jinchen [3 ]
Zheng, Xiaoxuan [1 ]
Xu, Jianlin [1 ]
Zhang, Hai [1 ]
Han, Baohui [1 ]
Zhong, Hua [1 ]
Zhang, Xueyan [1 ]
机构
[1] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Pulm, 241 West HuaihaiRd, Shanghai 200030, Peoples R China
[2] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Cent Lab, 241 West HuaihaiRd, Shanghai 200030, Peoples R China
[3] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Pathol, 241 West HuaihaiRd, Shanghai 200030, Peoples R China
关键词
Lung adenocarcinoma; EGFR; Micropapillary; Brain metastases; Surgical resection; HISTOLOGIC SUBTYPE; CANCER PATIENTS; CLASSIFICATION; PROGNOSIS; IMPACT; CHEMOTHERAPY; RISK;
D O I
10.1016/j.lungcan.2020.01.007
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: The role of micropapillary pattern (MIP) in EGFR-mutated NSCLC patients with brain metastases (BM) after complete surgical resection still remains unclear. Therefore, a retrospective study was conducted to evaluate the role of MIP in those patients. Methods: This study included 332 stage I-III patients with EGFR-mutant lung adenocarcinoma and complete resection. Patients were classified in four groups: the MIP-positive patients without BM development, the MIP-negative patients without BM development, the MIP-positive patients with BM development and the MIP-negative patients with BM development. Intracranial disease-free survival (iDFS), systemic disease-free survival (DFS) and overall survival (OS) were evaluated. Results: The median OS in the whole group was 70 months. The patients with MIP show inferior DFS (13 months vs. 22 months; P < 0.001) and OS (56 months vs. 74 months; P < 0.001). Furthermore, BM development was more likely to be found in patients with MIP (P = 0.001). In addition, the MIP-positive patients showed a significantly shorter iDFS compared with MIP-negative patients (14.5 months vs. 26 months; P < 0.001). Furthermore, the MIP-positive patients had significantly inferior iDFS in both BM as first line development groups (13 months vs. 19 months; P < 0.001) and BM as non-first line development groups (18 months vs. 33 months; P = 0.007). Conclusions: MIP was related to the earlier recurrence and shortened survival time. In addition, MIP was an independent poor prognostic factor for the increase of BM rate and the shortened time of BM development after surgery.
引用
收藏
页码:72 / 77
页数:6
相关论文
共 50 条
  • [21] EGFR Mutation Status, Liver Metastasis, and Overall Survival in Advanced Lung Adenocarcinoma Patients
    Walia, P.
    Zhan, L.
    Schmid, S.
    Brown, M. C.
    Khan, K.
    Garcia, M.
    Chowdhury, M.
    Herman, J.
    Sabouhanian, A.
    Strom, E.
    Patel, D.
    Cheng, S.
    Bradbury, P.
    Leighl, N.
    Sacher, A.
    Shepherd, F. A.
    Shultz, D.
    Liu, G.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1154 - S1155
  • [22] Comparison of prognosis between epidermal growth factor mutation positive and negative groups in lung adenocarcinoma patients with brain metastases
    Unat, Damla Serce
    Arikan, Sener
    Kirbiyik, Ozgur
    Balci, Guenseli
    Ermin, Sinem
    Mertoglu, Aydan
    EGYPTIAN JOURNAL OF BRONCHOLOGY, 2025, 19 (01)
  • [23] The impact of EGFR mutation status and single brain metastasis on the survival of non-small-cell lung cancer patients with brain metastases
    Fujita, Yuya
    Kinoshita, Manabu
    Ozaki, Tomohiko
    Takano, Koji
    Kunimasa, Kei
    Kimura, Madoka
    Inoue, Takako
    Tamiya, Motohiro
    Nishino, Kazumi
    Kumagai, Toru
    Kishima, Haruhiko
    Imamura, Fumio
    NEURO-ONCOLOGY ADVANCES, 2020, 2 (01)
  • [24] The correlation between EGFR mutation status and the risk of brain metastasis in patients with lung adenocarcinoma
    Bo Li
    Suo-zhu Sun
    Ming Yang
    Jian-ling Shi
    Wei Xu
    Xi-fan Wang
    Mao-min Song
    Huo-ming Chen
    Journal of Neuro-Oncology, 2015, 124 : 79 - 85
  • [25] EGFR-TKI Alone or with Concomitant Radiotherapy for Brain Metastases in Lung Adenocarcinoma Patients with EGFR Gene Mutations
    Chen, Yongshun
    Yang, Jing
    Li, Xue
    Hao, Daxuan
    Wu, Xiaoyuan
    Yang, Yuanyuan
    Hu, Xiaona
    He, Chunyu
    Wang, Wen
    Liu, Jinsong
    Wang, Jianhua
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S278 - S278
  • [26] A nomogram for predicting brain metastases of EGFR-mutated lung adenocarcinoma patients and estimating the efficacy of therapeutic strategies
    Wang, Jing
    Zhang, Baozhong
    Pang, Qingsong
    Zhang, Tian
    Chen, Xi
    Er, Puchun
    Wang, Yuwen
    You, Jinqiang
    Wang, Ping
    JOURNAL OF THORACIC DISEASE, 2021, 13 (02) : 883 - 892
  • [27] MRI-based radiomics analysis for predicting the EGFR mutation based on thoracic spinal metastases in lung adenocarcinoma patients
    Ren, Meihong
    Yang, Huazhe
    Lai, Qingyuan
    Shi, Dabao
    Liu, Guanyu
    Shuang, Xue
    Su, Juan
    Xie, Liping
    Dong, Yue
    Jiang, Xiran
    MEDICAL PHYSICS, 2021, 48 (09) : 5142 - 5151
  • [28] Micropapillary or solid pattern predicts recurrence free survival benefit from adjuvant chemotherapy in patients with stage IB lung adenocarcinoma
    Ma, Minjie
    She, Yunlang
    Ren, Yijiu
    Dai, Chenyang
    Zhang, Lei
    Xie, Huikang
    Wu, Chunyan
    Yang, Minglei
    Xie, Dong
    Chen, Chang
    JOURNAL OF THORACIC DISEASE, 2018, 10 (09) : 5384 - +
  • [29] Erlotinib Versus Radiation Therapy for Brain Metastases in Patients With EGFR-Mutant Lung Adenocarcinoma
    Gerber, Naamit K.
    Yamada, Yoshiya
    Rimner, Andreas
    Shi, Weiji
    Riely, Gregory J.
    Beal, Kathryn
    Yu, Helena A.
    Chan, Timothy A.
    Zhang, Zhigang
    Wu, Abraham J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 89 (02): : 322 - 329
  • [30] EGFR mutated non-small cell lung cancer patients: More prone to development of bone and brain metastases?
    Hendriks, L. E. L.
    Smit, E. F.
    Vosse, B. A. H.
    Mellema, W. W.
    Heideman, D. A. M.
    Bootsma, G. P.
    Westenend, M.
    Pitz, C.
    de Vries, G. J.
    Houben, R.
    Grunberg, K.
    Bendek, M.
    Speel, E-J M.
    Dingemans, A-M C.
    LUNG CANCER, 2014, 84 (01) : 86 - 91